Palatin Technologies, Inc.
Climate Impact & Sustainability Data (2019, 2023-08, 2024)
Reporting Period: 2019
Environmental Metrics
Climate Goals & Targets
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2023-08
Environmental Metrics
Climate Goals & Targets
Supply Chain Management
Climate-Related Risks & Opportunities
Reporting Period: 2024
Environmental Metrics
Climate Goals & Targets
Long-term Goals:
- NDA potential target submission for Bremelanotide/MC4R + PDE5i by 2027
- NDA File for PL9643 by 2026, FDA Approval/Launch by 2027
- NDA File for PL9588 by 2028, FDA Approval/Launch by 2029
Medium-term Goals:
- Novel MC4R Selective Long-Lasting Agonist – IND Filing / SAD/MAD Start by 4Q 2025
- PL7737 MC4R Oral Small Molecule Agonist – IND Filing / SAD/MAD Start by 4Q 2025
- Phase 2/3 Clinical Study Initiation for Bremelanotide/MC4R + PDE5i by 2H 2025
Short-term Goals:
- Data Readout for Obesity - MC4R Agonists – Weight Loss (Maintenance) Phase 2 BMT-801 Clinical Study by 1Q 2025
- PL9643 – Dry Eye Disease (DED) Phase 3 Melody-2 and -3 Phase 3 Pivotal Clinical Trials Initiation Target by 1Q 2025
- PL8177 Oral – Ulcerative Colitis Phase 2 Proof-of-Concept – Topline Data Readout by 1Q 2025
- Bremelanotide/MC4R + PDE5i (Co-Formulation Single Injection) – Erectile Dysfunction (ED) Development and Clinical Study Program in PDE5i Non-Responder ED Patients Initiated by 2Q 2025
- Pharmacokinetics (PK) Study for Bremelanotide/MC4R + PDE5i by 2H 2025